<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097405</url>
  </required_header>
  <id_info>
    <org_study_id>IBIO-203</org_study_id>
    <nct_id>NCT04097405</nct_id>
  </id_info>
  <brief_title>Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, and Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of D-0120 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InventisBio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InventisBio Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 1 study is a randomized, double-blind, placebo controlled, multiple-dose,
      dose-escalating study to evaluate the safety, tolerability, PK and PD of D-0120 in healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 18, 2019</start_date>
  <completion_date type="Anticipated">August 24, 2020</completion_date>
  <primary_completion_date type="Actual">March 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double Blind, placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects with treatment related adverse events as assessed</measure>
    <time_frame>Reporting of adverse events starts at enrollment through the end of the follow up period (14 days (cohorts 1-4) and 16 days (cohort 6)</time_frame>
    <description>Data will include clinical observations, ECG, clinical chemistry/hematology/urinalysis and vital signs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to observed Cmax (Tmax)for D-0120</measure>
    <time_frame>Timeframe: Day 1-Day7</time_frame>
    <description>Blood samples will be collected to assess plasma concentrations of D-0120 at a series of timepoints to derive Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) for D-0120</measure>
    <time_frame>Day 1-Day 7</time_frame>
    <description>Blood samples will be collected to assess plasma concentration of D-0120 at a series of timepoints to derive AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of D-0120</measure>
    <time_frame>Day 1-Day 7</time_frame>
    <description>Blood samples will be collect to assess plasma concentrations of D-0120 at a series of timepoints to derive Cmax</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>D-0120 Dose Ascending Cohorts 1-4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>D-0120 dose daily for up to 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Dose Ascending Cohorts 1-4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dose daily for up to 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D-0120/Uric Acid Lowering Agent Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-0120 in combination with a uric acid lowering agent for up to 7 days of combination therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-0120</intervention_name>
    <description>Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo</description>
    <arm_group_label>D-0120 Dose Ascending Cohorts 1-4</arm_group_label>
    <arm_group_label>D-0120/Uric Acid Lowering Agent Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo</description>
    <arm_group_label>Placebo Dose Ascending Cohorts 1-4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be medically documented as healthy at physical examination

          -  Moderate smokers or non-smokers

          -  Subjects must be between the ages of 18 and 60

          -  Subject must have a BMI between 18.0 and 30.0 kg/m2 (inclusive)

          -  Subjects must have a body weight of 50kg or higher for males and 45kg or higher for
             females

          -  Females must be non-pregnant and non-lactating, and either surgically sterile at least
             6 months prior to the first study drug administration or post-menopausal for 12 months
             or greater

          -  Male subjects who are not vasectomized for at least 6 months, and who are sexually
             active with non-sterile female partner must be willing to use an acceptable
             contraceptive method throughout the study and for 90 days after the last study drug
             administration

          -  Male subjects with a pregnant partner must agree to use a condom from the first dosing
             until at least 90 days after the last study administration

          -  Subjects must have a complete blood count and platelet count within the normal range

          -  Subjects must have a normal urinalysis

          -  Subjects must have a normal estimated glomerular filtration rate

          -  Subjects must have a normal ECG

          -  Subjects must be able to understand the study procedures, risks involved and be able
             to comply with the study and follow-up procedures

          -  Male subjects must be willing not to donate sperm until 90 days following the last
             study drug administration

        Exclusion Criteria:

          -  Subjects with any history or clinical manifestations of disorders

          -  Subjects who have any history or suspicion of kidney stones

          -  Subjects who are HIV, Hep B or Hep C positive

          -  History of significant allergic reactions to any drug

          -  Clinically significant ECG abnormalities

          -  History of significant drug abuse within 1 year prior to screening or use of soft
             drugs within 3 months prior to screening or hard drugs within 1 year prior to
             screening

          -  Subjects who have used prescription dugs, over the counter drugs or herbal remedies
             within 14 days before day 1

          -  Positive urine drug screen, alcohol breath at screening

          -  Subjects had undergone major surgery within 3 months

          -  Women who are pregnant or breastfeeding

          -  History of significant alcohol abuse

          -  Subjects who consumed Seville oranges-or grapefruit-containing food or beverages
             within 7 days before Day 1 and during the entire study duration.

          -  Subjects with any condition that, in the judgement of the investigator, would place
             him/her at undue risk

          -  Participation in a clinical research study involving the administration of an
             investigation or marketed drug or device within 30 days prior to the first dosing,
             administration of a biological product in the context of a clinical research study
             within 90 days prior to first dose

          -  Donation of plasma within 7 days prior to dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Syneos Health</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

